Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
NCT05799378
This study is recruiting at 11 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, the risk of HCQ retinal toxicity escalates with continued use. Evaluation using sensitive standard of care approaches suggests nearly a third of patients accrue retinal damage.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Systemic Lupus Erythematosus
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- NYU Langone Health
- Last updated on ClinicalTrials.gov
- August 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- University of California, Los Angeles · Los Angeles, CA
- University of California: San Diego · San Diego, CA
Georgia · 1
- Emory University School of Medicine · Atlanta, GA
New Jersey · 1
- Hackensack Meridian Health · Hackensack, NJ
New York · 5
- Columbia University Irving Medical Center/New York Presbyterian · New York, NY
- Hospital for Special Surgery · New York, NY
- NYC Health + Hospitals/Bellevue · New York, NY
- NYU Langone Health · New York, NY
- VA NY Harbor Healthcare System · New York, NY
Oklahoma · 1
- Oklahoma Medical Research Foundation · Oklahoma City, OK
Pennsylvania · 1
- Penn State MS Hershey Medical Center · Hershey, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.